ロード中...
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are either resistant or unable to tolerate another tyrosine kinase...
保存先:
| 出版年: | Blood Lymphat Cancer |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6467344/ https://ncbi.nlm.nih.gov/pubmed/31360088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S130197 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|